問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol Number8951-CL-5201
NCT Number(ClinicalTrials.gov Identfier)-
Active

2019-04-01 - 2027-11-30

Phase II

Recruiting9

ICD-10C25.9

Malignant neoplasm of pancreas, unspecified

ICD-10Z51.12

Encounter for antineoplastic immunotherapy

ICD-9157.9

Malignant neoplasm of pancreas, part unspecified

-

  • Trial Applicant

    ICON Clinical Research Pte Ltd

  • Sponsor

    -

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/05/15

Investigators and Locations

Principal Investigator Li-Yuan Bai Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Chung-Pin Li Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 馮盈勳 Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Li-Tzong Chen Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 林正耀 Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Tzeon-jye Chiou Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Yao-Yu Hsieh Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator SHIH-HUNG YANG

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Study Contacts

- -

Condition/Disease

-

Objectives

-

Test Drug

-

Active Ingredient

-

Dosage Form

-

Dosage

-

Endpoints

-

Inclution Criteria

-

Exclusion Criteria

-

The Estimated Number of Participants

  • Taiwan

    25 participants

  • Global

    369 participants